Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364790 | 0.94 | EPHX1 (0.47) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364445 | 0.91 | EPHX1 (0.51) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364166 | 0.89 | EPHX1 (0.44) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364173 | 0.86 | HCAR2 (0.43) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364880 | 0.84 | EPHX1 (0.53) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364170 | 0.83 | EPHX1 (0.47) | EPHX1HCAR2TSHRATMMAPT | |
| SCHEMBL18364178 | 0.82 | HCAR2 (0.48) | HCAR2ATMMAPTLMNAMDM2 | |
| SCHEMBL18364179 | 0.82 | HCAR2 (0.48) | HCAR2ATMMAPTLMNAMDM2 | |
| SCHEMBL22419399 | 0.81 | TSHR (0.46) | EPHX1TSHRMAPTHSD17B10ALDH1A1 | |
| SCHEMBL18406333 | 0.81 | HCAR2 (0.47) | HCAR2ATMMAPTLMNAMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008835-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | EPHX1 2795/4885HCAR2 290/4885TSHR 4688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.